Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors-Reference-Cited by-同舟云学术

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors

Published:2010-03-15 Issue:6 Volume:116 Page:1582-1591
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Johnson Faye M.,Agrawal Shruti,Burris Howard,Rosen Lee,Dhillon Navneet,Hong David,Blackwood-Chirchir Anne,Luo Feng R.,Sy Oumar,Kaul Sanjeev,Chiappori Alberto A.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.24927/fullpdf

Reference26 articles.

1. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy;Johnson;Anticancer Agents Med Chem.,2007

2. Increase in activity and level of pp60c-Src in progressive stages of human colorectal cancer;Talamonti;J Clin Invest.,1993

3. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest;Moasser;Cancer Res.,1999

4. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice;Yezhelyev;Clin Cancer Res.,2004

5. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model;Trevino;Am J Pathol.,2006

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous determination of three tyrosine kinase inhibitors and three triazoles in human plasma by LC-MS/MS: applications to therapeutic drug monitoring and drug-drug interaction studies;Journal of Chromatography B;2024-10

2. In Vitro Assessment of Inhibitory Effects of Kinase Inhibitors on CYP2C9, 3A and 1A2: Prediction of Drug-Drug Interaction Risk with Warfarin and Direct Oral Anticoagulants;European Journal of Pharmaceutical Sciences;2024-08

3. Comment on: “CYP3A4*22 Genotype‑Guided Dosing of Kinase Inhibitors in Cancer Patients”;Clinical Pharmacokinetics;2024-05-11

4. A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions;CPT: Pharmacometrics & Systems Pharmacology;2024-05

5. Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective;Critical Reviews in Oncology/Hematology;2024-03